Weizmannia coagulans BCF-01: a novel gastrogenic probiotic for Helicobacter pylori infection control.

The widespread prevalence of Helicobacter pylori infection, particularly in China, contributes to the development of gastrointestinal diseases. Antibiotics have limitations, including adverse reactions and increased antibiotic resistance. Therefore, identification of novel gastrogenic probiotics capable of surviving the acidic gastric environment and effectively combating H. pylori infection has potential in restoring gastric microbiota homeostasis. Five novel strains of human gastrogenic Weizmannia coagulans (BCF-01-05) were isolated from healthy gastric mucosa and characterized using 16S rDNA identification. Acid resistance, H. pylori inhibition, and adherence to gastric epithelial cells were evaluated in in-vitro experiments and the molecular mechanism explored in in-vivo experiments. Among the gastric-derived W. coagulans strains, BCF-01 exhibited the strongest adhesion and H. pylori inhibition, warranting further in-vivo safety evaluation. Through 16S rRNA sequencing of a mouse model, BCF-01 was determined to significantly restore H. pylori-associated gastric dysbiosis and increase the abundance of potential probiotic bacteria. Furthermore, BCF-01 enhanced mucosal tight junction protein expression and inhibited the TLR4-NFκB-pyroptosis signaling pathway in macrophages, as demonstrated by qRT-PCR and western blotting.These findings highlight the potential of BCF-01 in the prevention and control of H. pylori infection. Specifically, treatment with BCF-01 effectively restored gastric microecology and improved H. pylori-mediated mucosal barrier destruction while reducing inflammation through inhibition of the TLR4-NFκB-pyroptosis signaling pathway in macrophages. BCF-01 is a promising alternative to traditional triple therapy for H. pylori infections, offering minimal side effects with high suitability for high-risk individuals.

The Mechanism of Ginseng and Astragalus Decoction in the Treatment of Malignant Pleural Effusion Based on Network Pharmacology and Molecular Docking Technology.

Introduction: The objective of our study is to explore the potential active ingredients and activity of Ginseng and Astragalus decoction (GAD) in the treatment of malignant pleural effusion (MPE) by using network pharmacology and molecular docking technologies. Methods: The active ingredients and corresponding targets of Ginseng and Astragalus were extracted from the Traditional Chinese Medicine System Pharmacology Database and Analysis Platform. The relevant targets of malignant pleural effusion (MPE) were searched in the disease databases. Overlapping targets of Ginseng and Astragalus and the corresponding targets of MPE were obtained to define the effective target of GAD for the treatment of MPE. The STRING database was applied to construct a predicted protein-protein interaction network for intersected targets. The Cytoscape software was used to screen key targets with a therapeutic potential. Using the Metascape database, we performed Gene Ontology and Kyoto Encyclopedia of Genes and Genomes functional enrichment analysis on the targets identified in the study. PyMOL and AutoDock Vina were used to molecularly dock the selected key components to their respective key targets for MPE treatment. Results: The core target network revealed 22 main active ingredients, 26 main targets, and 16 signaling pathways in GAD. Molecular docking revealed 6 targets (AKT serine/threonine kinase 1, intercellular adhesion molecule, Jun proto-oncogene, peroxisome proliferator activated receptor gamma, prostaglandin-endoperoxide synthase 2, and tumor necrosis factor) that could partially dock with kaempferol, frutinone A, ginsenoside RH2, formononetin, and quercetin. Conclusions: Several components, targets, and signaling pathways of GAD contribute to the treatment of MPE, which suggests a rationale for further investigation on GAD's active molecule and mechanism of action in the clinical application of MPE.

Effect of cardiac rehabilitation training on patients with coronary heart disease: a systematic review and meta-analysis.

BACKGROUND: In recent years, the incidence of heart disease has increased and patients are younger. Cardiac rehabilitation training has been proposed to improve the prognosis of patients with heart disease. Cardiac rehabilitation includes moderate-intensity continuous training (MCT) and high-intensity interval training (HIIT). These two training methods have different effects in improving the prognosis of patients. The aim of the present study was to improve reference for patients with cardiac rehabilitation. METHODS: English databases, including PubMed, Cochrane Library, and Embase, were searched from the establishment of the database to April 2021 for randomized controlled trials (RCTs) of rehabilitation training at different intensities. RevMan 5.3 was used for the meta-analysis. RESULTS: A total of 8 articles (with a total of 465 patients) were included, including 236 patients in the experimental group and 229 patients in the control group. Different intensities of training had statistically significant differences in peak oxygen uptake [mean difference (MD): 1.21, 95% confidence interval (CI): -0.66 to 3.07, P=0.20] and the left ventricular ejection fraction difference (MD: 2.53, 95% CI: -2.10 to 7.17, P=0.28). DISCUSSION: Cardiac rehabilitation training can effectively improve the patient's cardiac function indicators and self-care ability, and reduce the incidence of cardiovascular disease (CVD). However, large-sample, multicenter, and long-term RCTs are needed to strengthen the findings of the study.